Moderna Entered into a Research and Development Collaboration with Immatics to Develop Innovative Oncology Therapies
- Immatics will receive $120M up front & research funding, ~$1.7B in milestones along with royalties on global net sales of TCER & vaccine products. Immatics gets an option for global profit & loss share arrangement for the most advanced TCER
- Moderna will be responsible for the clinical development & commercialization of cancer vaccines and TCER therapeutics. Immatics will conduct the preclinical studies & P-I trials for the IMA203 TCR-T + PRAME mRNA vaccine to enhance IMA203 T cell responses while each party will retain full ownership of the PRAME compound & will fund the clinical study on a cost-sharing basis
- The collaboration combines technologies to develop mRNA-enabled in vivo expressed TCER molecules; combines Immatics’ XPRESIDENT target discovery platform & Moderna’s mRNA technology for novel cancer vaccines. The collaboration incl. the evaluation of Immatics’ IMA203 PRAME TCR-T + Moderna’s PRAME mRNA cancer vaccine
Ref: Globenewswire | Image: Moderna
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.